See more : MonotaRO Co., Ltd. (3064.T) Income Statement Analysis – Financial Results
Complete financial analysis of IGEA Pharma N.V. (IGPH.SW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IGEA Pharma N.V., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- International Graphite Limited (IG6.AX) Income Statement Analysis – Financial Results
- Argenica Therapeutics Limited (AGN.AX) Income Statement Analysis – Financial Results
- Hancom Inc. (030520.KQ) Income Statement Analysis – Financial Results
- Lions Bay Mining Corp. (LMNGF) Income Statement Analysis – Financial Results
- Minda Corporation Limited (MINDACORP.NS) Income Statement Analysis – Financial Results
IGEA Pharma N.V. (IGPH.SW)
About IGEA Pharma N.V.
IGEA Pharma N.V. commercializes health-tech and med-tech products and devices in in the United States and the Netherlands. It offers Alz1, an at-home lab test kit to measure non-bound copper in the blood; dietary supplement products to reduce blood heavy metals content under the Alz1 Tab brand; and COVID19 rapid test for the detection of IgM and IgG SARS-CoV-2 related antibodies. The company also provides dry aerosol generators for air and inanimate environmental surfaces sanitization, as well as air sterilization and purification devices. In addition, it engages in laboratory analysis. The company was incorporated in 2015 and is headquartered in Hoofddorp, the Netherlands.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 103.30K | 64.39K | 1.25K | 5.15K | 6.50K |
| Cost of Revenue | 0.00 | 126.20K | 236.51K | 392.71K | 173.01K | 170.15K |
| Gross Profit | 0.00 | -22.90K | -172.12K | -391.46K | -167.86K | -163.65K |
| Gross Profit Ratio | 0.00% | -22.17% | -267.30% | -31,321.39% | -3,260.65% | -2,518.02% |
| Research & Development | 13.40K | 148.90K | 48.21K | 109.00K | 0.00 | 0.00 |
| General & Administrative | 9.56M | 1.15M | 464.81K | 750.87K | 1.12M | 154.47K |
| Selling & Marketing | 0.00 | 200.00 | 143.34K | 471.98K | 0.00 | 0.00 |
| SG&A | 9.56M | 1.15M | 608.15K | 1.22M | 1.12M | 154.47K |
| Other Expenses | 0.00 | -179.90K | -43.82K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.57M | 1.12M | 612.54K | 1.33M | 1.12M | 154.47K |
| Cost & Expenses | 9.57M | 1.25M | 849.06K | 1.72M | 1.29M | 324.62K |
| Interest Income | 0.00 | 2.30K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 300.00 | 6.50K | 2.11K | 6.07K | 14.99K | 30.33K |
| Depreciation & Amortization | 886.70K | -107.40K | -61.47K | 155.60K | 66.32K | 63.24K |
| EBITDA | -9.57M | -1.25M | -846.13K | -1.57M | -1.17M | -265.78K |
| EBITDA Ratio | 0.00% | -1,212.39% | -1,314.03% | -125,392.86% | -22,750.89% | -4,089.53% |
| Operating Income | -10.46M | -1.15M | -784.66K | -1.72M | -1.28M | -318.12K |
| Operating Income Ratio | 0.00% | -1,108.42% | -1,218.58% | -137,842.86% | -24,917.30% | -4,894.77% |
| Total Other Income/Expenses | -1.30M | -113.90K | -140.82K | 19.55K | 34.51K | -41.24K |
| Income Before Tax | -11.75M | -1.26M | -925.48K | -1.70M | -1.25M | -359.35K |
| Income Before Tax Ratio | 0.00% | -1,218.68% | -1,437.26% | -136,278.57% | -24,246.93% | -5,529.25% |
| Income Tax Expense | 24.50K | 102.40K | 1.54K | 4.82K | 61.54K | -92.20K |
| Net Income | -11.69M | -1.36M | -927.03K | -1.71M | -1.24M | -278.06K |
| Net Income Ratio | 0.00% | -1,317.81% | -1,439.66% | -136,664.29% | -24,178.94% | -4,278.41% |
| EPS | -0.03 | 0.00 | 0.00 | -0.07 | -0.05 | -0.01 |
| EPS Diluted | -0.03 | 0.00 | 0.00 | -0.07 | -0.05 | -0.01 |
| Weighted Avg Shares Out | 336.50M | 314.46M | 307.20M | 25.02M | 22.93M | 20.00M |
| Weighted Avg Shares Out (Dil) | 336.50M | 314.46M | 307.20M | 25.02M | 22.93M | 20.00M |
Source: https://incomestatements.info
Category: Stock Reports